Related Experiment Video

Updated: Jan 22, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K

The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors

Omar Alkharabsheh1, M Hasib Sidiqi2, Mohammed A Aljama3

  • 1Division of Medical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA, oalkharabsheh@health.southalabama.edu.

Acta Haematologica
|July 17, 2019
PubMed

Insights

The gut microbiota influences multiple myeloma (MM) progression and treatment outcomes. Understanding its role is crucial for managing MM, its therapies, and associated gastrointestinal side effects.

Area of Science:

  • Microbiology
  • Oncology
  • Immunology

Background:

  • The gut microbiota significantly impacts cancer development and treatment efficacy.
  • Multiple myeloma plasma cells can persist in the gastrointestinal tract, influenced by the microbiota.
  • Gut microbes affect antigen stimulation, potentially driving myeloma mutation and evolution.

Purpose of the Study:

  • To review the gut microbiota's role in hematopoiesis and multiple myeloma pathogenesis.
  • To examine the impact of gut microbiota on the efficacy and toxicity of anti-myeloma therapies.
  • To explore the link between gut microbiota and gastrointestinal adverse events from myeloma treatments.

Main Methods:

  • Literature review synthesizing current research on gut microbiota and multiple myeloma.
  • Analysis of studies investigating microbial influence on plasma cell behavior and immune response.
  • Examination of data on the side effects of common multiple myeloma therapies.

Main Results:

  • The gut microbiota composition affects antigen stimulation of myeloma cells.
  • Microbiota plays a role in the efficacy and toxicity of novel therapies and immunotherapy.
  • Common myeloma treatments like proteasome inhibitors cause gastrointestinal adverse events.

Conclusions:

  • The gut microbiota is a key factor in multiple myeloma development and treatment.
  • Targeting the gut microbiota may improve therapeutic outcomes and reduce toxicity in multiple myeloma patients.
  • Further research is needed to elucidate specific microbial mechanisms in multiple myeloma.
Keywords:
MicrobiotaMultiple myelomaProteasome inhibitors

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.7K

Related Concept Videos

The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.1K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.7K
The Proteasome02:18

The Proteasome

4.5K
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
1.6K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
38.0K